← Leaderboards
Jenny Yaohua Xue
Weill Medical Coll Of Cornell Univ
$190,741
Attributed
$190,741
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $50.5K · FY2018–21$100K$75K$50K$25K$0
'18
'19
'20
'21
Funding mix
By agency
NIH$190,741 · 1
By mechanism
F30$190,741 · 1
Top collaborators
No co-investigators on record.
Most similar at Weill Medical Coll Of Cornell Univ
Same institution · by research overlap
- Vivek Mittal$10,850,597
- Nasser Khaled Altorki$2,970,612
- Steven Monroe Lipkin$27,661,021
- Olivier Elemento$10,592,678
- Alain C Borczuk$997,395
Others in their field
Other Emerging Leaders on “Advanced Disease”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Chanza Baytop · Westat, Inc.$271,217,917
- Kimberly Smith · Ppd Development Lp$116,656,661
- Klaus Romero · Critical Path Institute$88,602,036
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Ted Ross · University Of Georgia$59,913,818
Research focus
Advanced DiseaseAntitumor ResponseArchitectureAffectBaseBraf GeneBurden Of IllnessCell LineCellsClonal EvolutionClonal ExpansionClone CellsColorectal CancerCombined Modality TherapyDesignDisadvantagedDna SequencingDrug CombinationsEffective TherapyEvolutionExtinction (Psychology)FitnessGrowthInhibitor/Antagonist
Grant awards (4)
Dissecting the evolution of targeted therapy resistance in BRAFV600E-mutant cancer$48,007
F30 · FY2021 · CA · contact PI
Dissecting the evolution of targeted therapy resistance in BRAFV600E-mutant cancer$50,520
F30 · FY2020 · CA · contact PI
Dissecting the evolution of targeted therapy resistance in BRAFV600E-mutant cancer$46,353
F30 · FY2019 · CA · contact PI
Dissecting the evolution of targeted therapy resistance in BRAFV600E-mutant cancer$45,861
F30 · FY2018 · CA · contact PI